OncoMatch/Clinical Trials/NCT07441993
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Is NCT07441993 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Orelabrutinib for marginal zone lymphoma.
Treatment: Orelabrutinib — This is a single-arm, multicenter, prospective, phase II study. The primary objective is to assess the efficacy and safety of orelabrutinib in treatment-naïve patients with marginal zone lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage I, II
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, platelets ≥75×10^9/L, hemoglobin ≥75g/L; if bone marrow involvement: ANC ≥1.0×10^9/L, platelets ≥50×10^9/L, hemoglobin ≥50g/L
Kidney function
serum creatinine ≤1.5×ULN
Liver function
Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN
Cardiac function
NYHA Class II or higher congestive heart failure, unstable angina, MI within 6 months, arrhythmia requiring treatment, LVEF <50%, primary cardiomyopathy, QTc >470 ms (female) or >450 ms (male), symptomatic coronary artery disease requiring medication, poorly controlled hypertension
Blood tests: ANC ≥1.5×10^9/L, platelets ≥75×10^9/L, hemoglobin ≥75g/L; if accompanied by bone marrow involvement, ANC ≥1.0×10^9/L, platelets ≥50×10^9/L, hemoglobin ≥50g/L; Blood biochemistry: Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN; serum creatinine ≤1.5×ULN; NYHA Class II or higher congestive heart failure, unstable angina, MI within 6 months, arrhythmia requiring treatment, LVEF <50%, primary cardiomyopathy, QTc >470 ms (female) or >450 ms (male), symptomatic coronary artery disease requiring medication, poorly controlled hypertension
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify